Flagship Pioneering

🚀 We’re thrilled to unveil the 2024 THRIVE Top50 AgTech & FoodTech Listings, highlighting the most innovative companies transforming the global agri-food industry. 🌱 🌍 These trailblazing companies are leading the charge in sustainable solutions and groundbreaking technologies that address critical environmental challenges. Dive into the report to discover who’s shaping the future of food and agriculture. 📄 Read the Full Report: https://lnkd.in/gNSbNS3p 📰 Press Release: https://lnkd.in/gXrxDbKG Join us in celebrating these incredible innovators! #AgTech #FoodTech #Innovation #Sustainability #THRIVETop50

Attend #medSCAI24—our third annual symposium on medicines, single cell technology and #AI! Join esteemed industry leaders for two sessions focused on AI and #MachineLearning-powered #DrugDiscovery.   Hear from Arpeggio Biosciences CEO Joey Azofeifa and professors Paul Blainey, from MIT Department of Biological Engineering, and Cole Trapnell, from University of Washington’s Department of Genome Sciences in ‘Session 1: From Data to New Biology.’   Caroline Gubser Keller, Global Head of Data Science at Novartis BioMedical Research, will lead ‘Session 2: From Biology and Computation to Translation’ with a discussion about innovative applications of AI and ML.   Register Today ➡️ https://bit.ly/3yOdJEL

What a special afternoon! Today I had the honor of delivering the convocation address at UMass Boston. Feelings of both pride and humility filled me as I looked into the sea of eager, vibrant faces, ready to kickstart another academic year. I am profoundly touched by the UMass Boston spirit of making education accessible to students from all walks of life, helping them to thrive and reach their full potential. I want to sincerely thank Chancellor Marcelo M Suarez-Orozco, Provost Joe Berger, and the entire UMass community for giving me the opportunity to contribute to this important day. This was also opportunity for me personally to reflect on the experiences that have shaped my life and career Flagship Pioneering. I had the chance to discuss the power of neighborhoods, both physical and metaphorical, and how when you leave the comfort of these neighborhoods to explore new directions, you can foster vibrant new connections and tap into the endless possibilities where disciplines intersect. It is here where innovation thrives. To celebrate the new academic year, you can watch a replay of the ceremony here: https://lnkd.in/e6ZikYNg #UMassBoston #innovation #BiggerLeaps #WeAreFlagship

We are thrilled to welcome the newest member of the Sana senior leadership team Dhaval Patel, M.D., Ph.D., who joined as Executive Vice President and Chief Scientific Officer. We look forward to partnering with him to accelerate our journey towards delivering engineered cells as medicines for patients. #sanabiotechnology #leadership #OneSana

Today we’re pleased to share Cohort 2 data from our Phase 1b study evaluating SER-155 in patients undergoing allo-HSCT. Read the full release here: https://lnkd.in/ekKD-Tqf --- Summary of Cohort 2 Results (through day 100 post HSCT) - SER-155 was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia - SER-155 demonstrated a generally well tolerated safety profile and had confirmed drug bacteria strain engraftment; no treatment-related serious adverse events were observed - Seres will seek Breakthrough Therapy designation from the FDA and discuss plans to advance development of SER-155 in allo-HSCT.

Introducing the CLIPS device, an innovative dry powder application system. Offering an improved planting window, eliminated application steps, reduced opportunity for exposure, and even product coatings, CLIPS streamlines biotrinsic® seed treatments.

We are so excited to share that FierceHealth and Fierce Life Sciences have named Alltrna’s CEO Michelle Werner as one of 𝟮𝟬𝟮𝟰’𝘀 #𝗙𝗶𝗲𝗿𝗰𝗲𝟱𝟬 𝗵𝗼𝗻𝗼𝗿𝗲𝗲𝘀! It’s great to see the recognition for her leadership at Alltrna as we pioneer #tRNA medicines and her commitment to innovation, equity, and improving patient lives – especially those with rare diseases. Read the profile here: https://lnkd.in/gBEHQeVe Congrats Michelle and thank you for all you do! #PatientAdvocacy #tRNAmedicines #rarediseases #raredisease #StopCodonDisease #geneticmedicines #programmablemedicines

Duchenne muscular dystrophy has seen more progress in the past 15 months (give or take) than in the last couple of decades combined, with three new therapies approved by the FDA, including the gene therapy Elevidys. But what I think many in the field fail to understand is that while families now have more hope, they are also feeling overwhelmed, anxious, confused, and, quite frankly, scared to death. As many of you know, I'm not only the CEO of Alltrna, but I'm also the mother of a child with Duchenne. My husband and I agonized over the decision about whether to seek treatment with Elevidys for our son Caffrey, which comes with considerations that could last a lifetime. Ultimately it was Caffrey, now 14, who made the final decision, opting not to pursue the treatment. As I outline in this STAT First Opinion article and as we recognize during this year’s World Duchenne Awareness Day, parents need to step up as advocates for their kids like never before. And when the stakes are so high and the decision is so personal, the most critical thing families need is judgment-free support. It has been a historic year, one that makes me so optimistic about the future, but let’s remember that Duchenne is far from being solved. We cannot stop innovating until this is achieved. Read the First Opinion article: https://lnkd.in/e7qmKQuK #Duchenne #musculardystrophy #WorldDuchenneAwarenessDay #DuchenneActionMonth #WDAD2024 #MuscularDystrophyAwarenessMonth #30DaysOfStrength